Biotech Values

[jq1234]

>> There's already an enormous pool of patients who failed treatment on PD-(L)1-containing regimens, mostly monotherapy failures.

Yes, but no one including BMY has insider track to capture that market yet. My assessment in my previous post is very close to JohnWayne's on current IO space status.